These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 5076123)

  • 21. [Clinical evaluation of a fribrinolytic drug in an experimental cross-over study].
    Bizzi B; Butti A
    Minerva Med; 1969 Dec; 60(99 Suppl):5062-7. PubMed ID: 4188590
    [No Abstract]   [Full Text] [Related]  

  • 22. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of a single dose of heparin on the fibrinolytic activity of plasma euglobulins and studies on blood coagulation in patients with obliterative arteriosclerosis of the lower extremities].
    Cencora A
    Folia Med Cracov; 1973; 15(2):207-27. PubMed ID: 4758953
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
    Motomiya T
    Nihon Naika Gakkai Zasshi; 1970 Feb; 59(2):117-25. PubMed ID: 4910199
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of parmidine (pyridinolcarbamate) on thrombocyte aggregation, blood clotting and fibrinolysis].
    Mashkovskiĭ MD; Lakin KM; Ovnatanova MS; Shvarts GIa
    Biull Eksp Biol Med; 1976 Mar; 81(3):322-4. PubMed ID: 953280
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis].
    Majkowski J; Lysakowska-Sernicka K; Gajewska A; Bilińska-Nigot B; Ostrowski K; Semenicki K
    Neurol Neurochir Pol; 1978; 12(4):387-96. PubMed ID: 714218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [On some aspects of therapy of chronic peripheral obliterating arteriopathies (C.P.O.A.) on arteriosclerotic nature].
    Seghezzi R; Borri P; Pedroni G
    Minerva Med; 1968 Dec; 59(99):5458-65. PubMed ID: 5718833
    [No Abstract]   [Full Text] [Related]  

  • 30. Failure of vasodilator drugs in arteriosclerosis obliterans.
    Coffman JD; Mannick JA
    Ann Intern Med; 1972 Jan; 76(1):35-9. PubMed ID: 4553743
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical and coagulation physiological studies on a protease from Aspergillus ochraceus (preliminary report)].
    Vogel G; Grossmann K; Huyke R; Zuber W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(1):125-31. PubMed ID: 4134261
    [No Abstract]   [Full Text] [Related]  

  • 32. Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans.
    Grodzińska L; Basista M; Kedzior A; Korbut R; Kostka-Trabka E; Gryglewski R
    Thromb Haemost; 1983 Dec; 50(4):797-9. PubMed ID: 6364447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appearance of thrombogenic tendency induced by adrenaline and its prevention by -adrenergic blocking agent, nialamide and pyridinolcarbamate.
    Yamazaki H; Sano T; Odakura T; Takeuchi K; Matsumura T; Hosaki S; Shimamoto T
    Thromb Diath Haemorrh; 1971 Oct; 26(2):251-63. PubMed ID: 4400009
    [No Abstract]   [Full Text] [Related]  

  • 34. [Considerations on the activation of the regional fibrinolytic system of the extremities in subjects with obliterating arteriopathy with a malignant course].
    Brunetti S; Tesi M; Caramelli L
    Riv Crit Clin Med; 1967 Dec; 67(6):443-54. PubMed ID: 5603689
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of arteriosclerosis obliterans with pyridinolcarbamate].
    Atsumi T; Isokane N; Yamashita S; Sano T; Odakura T; Kurai A
    Nihon Naika Gakkai Zasshi; 1967 Sep; 56(9):983-92. PubMed ID: 5627161
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pyridinol carbamate in atherosclerosis].
    Sanwald R
    Dtsch Med Wochenschr; 1972 Apr; 97(14):583-4. PubMed ID: 5022146
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of pyridinolcarbamate on induced atherosclerosis in cynomolgus monkeys (Macaca ira).
    Malinow MR; McLaughlin P; Perley A
    Atherosclerosis; 1972; 15(1):31-6. PubMed ID: 4111120
    [No Abstract]   [Full Text] [Related]  

  • 38. Fibrinolytic effect of biguanides.
    Fearnley GR; Chakrabarti R; Hocking ED; Evans J
    Ann N Y Acad Sci; 1968 Mar; 148(3):840-7. PubMed ID: 5241480
    [No Abstract]   [Full Text] [Related]  

  • 39. [Thrombolytic agents and substances with "minor fibrinolytic" effect].
    Verstraete M; Amery A
    Rev Atheroscler (Paris); 1968; 10(2):21-7. PubMed ID: 5759946
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacologic principles of fibrinolytic therapy].
    Markwardt F
    Z Gesamte Inn Med; 1987 Sep; 42(17):473-8. PubMed ID: 3318182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.